Le Lézard
Classified in: Health
Subject: PDT

ColdZyme Launches With New Flavor and New Product Claims


STOCKHOLM, Aug. 26, 2019 /PRNewswire/ -- Enzymatica is now launching strawberry as its new flavor for ColdZyme® cold spray and also introducing two new product claims ? soothe sore throat and alleviate common cold symptoms. Strawberry flavored ColdZyme will be available in the majority of pharmacy chains in Sweden beginning in late August and it will be on the shelves of the remaining pharmacies from early October.

Many have requested a new flavor that appeals to both young and old, and now it is here! Enzymatica is expanding the ColdZyme family with ColdZyme Strawberry 20 ml. Studies and market surveys have shown that 20-25% of respondents prefer a flavor other than our current menthol flavor. The new flavor will be launched in Sweden and Denmark at the end of August, with product roll-out planned in other markets where ColdZyme is sold over the next few years.

ColdZyme has also received extended product claims stating that in addition to preventing and reducing the duration of colds, ColdZyme can also soothe sore throats and alleviate common cold symptoms.

"The new product claims are based on the successful results of our 2018 prospective, single-blind, randomized multicenter study in Germany. These results strengthen the documentation for ColdZyme as a safe and effective treatment for colds," says Fredrik Lindberg, CEO of Enzymatica.

The German multicenter study was carried out at six centers in Germany during the 2018 cold season. The study included 400 participants who were randomly asked either to initiate treatment with ColdZyme at the first cold symptoms, or not to start any treatment. A total of 267 people with confirmed colds were evaluated in the study. The results from the study strengthen ColdZyme's intended use of reducing the duration of colds, while also broadening its clinical benefit by showing that ColdZyme significantly reduces cold symptoms, soothe sore throats, improves quality of life and reduces the need for concurrent use of symptom-relieving medication for colds. 

For more information please contact: 
Fredrik Lindberg
CEO Enzymatica AB
Tel: +46 (0)708-86-53-70
Email: [email protected]   

Carl-Johan Wachtmeister
Head of Corporate Communications
Enzymatica AB
Tel: +46 (0)701-88-50-21 
Email: [email protected] 

About Enzymatica AB 

Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The company's first product is ColdZyme®, which can prevent colds and reduce the duration of disease. The product has been launched in about ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North. For more information, visit: www.enzymatica.com.  

Enzymatica's Certified Adviser is Erik Penser Bank.

Tel: +46 (0)8-463-83-00
Email: [email protected] 
Enzymatica AB Ideon Science Park 223 70 Lund
Phone: +46-46-286-31-00

www.enzymatica.se 
www.coldzyme.se 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/coldzyme-launches-with-new-flavor-and-new-product-claims,c2888196

The following files are available for download:

https://news.cision.com/enzymatica-ab/i/coldzyme-20-strawberry,c2670698

ColdZyme 20-strawberry

 


These press releases may also interest you

at 22:03
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

at 22:00
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...



News published on and distributed by: